A gene-editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test

Bioregnum Opinion Column by John Carroll

Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. As chief business officer and strategy chief for the Broad over a decade-long stretch, he’d worked with all the…

Advertisement — Advertise with Biotech Networks